Episode Details

This episode explores challenging medical prognoses, from inoperable tumors to dire timelines, highlighting the critical need for advanced patient care.

Dr. Prato discusses how precise oncology approaches can offer hope, even when traditional healthcare options seem limited. By focusing on personalized cancer treatment, we aim to redefine what's possible for every cancer patient.

🎯 What You’ll Learn in This Episode:

• What “2–3 months to live” typically means clinically
• Why cancer varies between patients
• The role of deeper biological testing
• What multi-omics analysis includes
• Why monitoring between scans matters
• The concept of immune-focused treatment strategies
• 5 key questions to ask your doctor
• How treatment planning may evolve over time

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“When cancer is complex, decisions should be guided by deeper data — not just timelines.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493